Media Summary: To cite: Eyerich K, Weisenseel P, Pinter A, et al. Dr. Tsoi discusses his research on the effects Ixekizumab and Dr. Laura Korb Ferris, MD, PhD, Professor, University of Pittsburgh Clinical and Translational Science Institute and Director of ...

Il 23 Blockade With Guselkumab Potentially Modifies Psoriasis Pathogenesis - Detailed Analysis & Overview

To cite: Eyerich K, Weisenseel P, Pinter A, et al. Dr. Tsoi discusses his research on the effects Ixekizumab and Dr. Laura Korb Ferris, MD, PhD, Professor, University of Pittsburgh Clinical and Translational Science Institute and Director of ... Dermatology experts remark on the impressive results of clinical data supporting the use of newer At the American College of Rheumatology (ACR) virtual meeting, positive results were announced from a phase III study ... Professor Iain McInnes, Associate Professor Laura Coates, Professor Christopher Ritchlin, and Professor Philip Mease present ...

There is an increasing focus on the importance of Author video for 'A head-to-head comparison of ixekizumab vs. Author video for 'A head‐to‐head comparison of ixekizumab vs.

Photo Gallery

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis
lxekizumab Reduces key IL-17 and IL-23 Pathway Genes More Rapidly than Guselkumab | Lam Tsoi, PhD
New Data Demonstrates Potential for Oral IL-23 in Psoriasis
Efficacy of IL-23 Inhibitors in Plaque Psoriasis
Exploring the Potential of Guselkumab in Psoriatic Arthritis - Medpage Today
IL-23s: Psoriasis therapy overview
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Mul... | RTCL.TV
Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar
Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD
IL23 & IL12/23 Inhibitors: An Overview
IL-23 Inhibitors and Other Emerging Psoriasis Treatments
Ixekizumab vs. guselkumab in plaque psoriasis, Blauvelt et al
Sponsored
Sponsored
View Detailed Profile
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis

To cite: Eyerich K, Weisenseel P, Pinter A, et al.

lxekizumab Reduces key IL-17 and IL-23 Pathway Genes More Rapidly than Guselkumab | Lam Tsoi, PhD

lxekizumab Reduces key IL-17 and IL-23 Pathway Genes More Rapidly than Guselkumab | Lam Tsoi, PhD

Dr. Tsoi discusses his research on the effects Ixekizumab and

Sponsored
New Data Demonstrates Potential for Oral IL-23 in Psoriasis

New Data Demonstrates Potential for Oral IL-23 in Psoriasis

Dr. Laura Korb Ferris, MD, PhD, Professor, University of Pittsburgh Clinical and Translational Science Institute and Director of ...

Efficacy of IL-23 Inhibitors in Plaque Psoriasis

Efficacy of IL-23 Inhibitors in Plaque Psoriasis

Dermatology experts remark on the impressive results of clinical data supporting the use of newer

Exploring the Potential of Guselkumab in Psoriatic Arthritis - Medpage Today

Exploring the Potential of Guselkumab in Psoriatic Arthritis - Medpage Today

At the American College of Rheumatology (ACR) virtual meeting, positive results were announced from a phase III study ...

Sponsored
IL-23s: Psoriasis therapy overview

IL-23s: Psoriasis therapy overview

People with moderate-to-severe

Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Mul... | RTCL.TV

Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Mul... | RTCL.TV

Keywords ### #psoriaticarthritis #PsAprogression #PAMPAstudy #increasedrisk #antibody #PAMPA #Dopplerultrasound ...

Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar

Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar

Professor Iain McInnes, Associate Professor Laura Coates, Professor Christopher Ritchlin, and Professor Philip Mease present ...

Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD

Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD

There is an increasing focus on the importance of

IL23 & IL12/23 Inhibitors: An Overview

IL23 & IL12/23 Inhibitors: An Overview

IL23

IL-23 Inhibitors and Other Emerging Psoriasis Treatments

IL-23 Inhibitors and Other Emerging Psoriasis Treatments

The

Ixekizumab vs. guselkumab in plaque psoriasis, Blauvelt et al

Ixekizumab vs. guselkumab in plaque psoriasis, Blauvelt et al

Author video for 'A head-to-head comparison of ixekizumab vs.

Ixekizumab vs. guselkumab in plaque psoriasis, A. Blauvelt et al

Ixekizumab vs. guselkumab in plaque psoriasis, A. Blauvelt et al

Author video for 'A head‐to‐head comparison of ixekizumab vs.